FDA cannabinoid regulation

“The FDA's failure to establish a regulatory pathway for CBD as a dietary supplement after five years of deliberation is not bureaucratic inertia — it is a policy choice with winners and losers. The losers are small hemp companies and consumers who deserve clarity. The winners are pharmaceutical interests and incumbent food companies.”

— Robert Hoban, Hoban Law Group

“The FDA's failure to establish a regulatory pathway for CBD as a dietary supplement after five years of deliberation is not bureaucratic inertia — it is a policy choice with winners and losers. The losers are small hemp companies and consumers who deserve clarity. The winners are pharmaceutical interests and incumbent food companies. Congress has the authority to force this issue through appropriations or standalone legislation, and there are signs that patience in both parties is exhausted. My expectation is that we will see legislative action on FDA hemp authority before the next farm bill reauthorization.”

— Robert Hoban, Hoban Law Group